logo
E3 Lithium and Imperial Finalize Freehold Mineral Land for E3's Clearwater Project

E3 Lithium and Imperial Finalize Freehold Mineral Land for E3's Clearwater Project

Yahoo03-03-2025

CALGARY, Alberta, March 03, 2025--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), "E3 Lithium" or the "Company," a leader in Canadian lithium, announced today it has finalized the rights and agreements for freehold mineral tenure held by Imperial Oil Limited (TSX:IMO) (NYSE:IMO), "Imperial" for the E3 Clearwater Project.
The companies have entered into a Project Completion Agreement dated February 28, 2025, 2025 (the "Project Completion Agreement") to finalize the rights and lease agreements for the freehold mineral tenure held by Imperial for E3's use in its Clearwater Project, pursuant to the Strategic Agreement dated June 22, 2022 and amended May 9, 2024 (the "Strategic Agreement").
As set out in the Strategic Agreement, Imperial has provided a mineral lease for 110 sections of the Imperial freehold interest in the area of the Clearwater Project. The long-term lease has a 10-year primary term with a renewable 10-year term on the mineral title. The Project Completion Agreement supersedes the Strategic Agreement and includes the cancellation of 3,413,979 warrants granted to Imperial at a pre-paid price of C$1.86 per warrant upon the payment by E3 of cash consideration in the aggregate amount of C$4,150,000. This amount will be payable in three installments over the first three quarters of 2025, with the warrants being cancelled in proportion to the installment payments.
E3 Lithium continues to build strong partnerships that are essential for driving success. E3's success on the pilot operations in 2023 has further bolstered the progress of E3's technology towards the demonstration program planned for 2025. The freehold mineral tenure for the Clearwater Project will allow E3 Lithium to build upon the success of the pilot operations as it looks to achieve its corporate and strategic goals of building lithium production in Alberta.
"This milestone underscores the strong relationship between Imperial and E3 Lithium," said Chris Doornbos, CEO of E3 Lithium. "It supports the interests of both companies while continuing to drive the success of E3's Clearwater Project and Alberta's position in the global lithium supply chain."
"Imperial's successful collaboration with E3 Lithium has been instrumental in advancing E3's lithium extraction pilot and progressing opportunities from the Leduc reservoir," said Heather Eggleston, Imperial Vice-President of Low Carbon Solutions. "Imperial's contribution of its freehold land leases provides further support for E3 Lithium's Clearwater Project and their overall lithium development in Alberta."
The Clearwater Project is a transformative opportunity for Alberta's critical minerals sector; by leveraging advanced extraction technologies and decades of energy expertise, E3 Lithium is positioned to be a global leader in lithium development.
ON BEHALF OF THE BOARD OF DIRECTORSChris Doornbos, President & CEOE3 Lithium Ltd.
About E3 Lithium
E3 Lithium is a development company with a total of 16.2 million tonnes of lithium carbonate equivalent (LCE) Measured and Indicated 1 as well as 0.9 million tonnes LCE Inferred mineral resources2 in Alberta and 2.5 million tonnes LCE Inferred mineral resources3 in Saskatchewan. The Clearwater Pre-Feasibility Study outlined a 1.13 Mt LCE proven and probable mineral reserve with a pre-tax NPV8% of USD 5.2 Billion with a 29.2% IRR and an after-tax NPV8% of USD 3.7 Billion with a 24.6% IRR1. E3 Lithium's goal is to produce high purity, battery grade lithium products to power the growing electrical revolution. With a significant lithium resource and innovative technology solutions, E3 Lithium has the potential to deliver lithium to market from one of the best jurisdictions in the world.
1: The Clearwater Pre-Feasibility Study ("PFS") news release dated June 26, 2024 is available on the E3 Lithium's website (e3lithium.ca/newsroom/news-releases/) and SEDAR+ (www.sedarplus.ca).
2: The mineral resource NI 43-101 Technical Report for the North Rocky Property, effective October 27, 2017, identified 0.9 Mt LCE (inferred) and is available on the E3 Lithium's website (e3lithium.ca/technical-reports) and SEDAR+ (www.sedarplus.ca).
3: The mineral resource NI 43-101 Technical Report for the Estevan Lithium District, effective May 23, 2024, identified 2.5 Mt LCE (inferred) and is available on the E3 Lithium's website (e3lithium.ca/technical-reports) and SEDAR+ (www.sedarplus.ca).
Forward-Looking and Cautionary Statements
This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the effectiveness and feasibility of emerging lithium extraction technologies which have not yet been tested or proven on a commercial scale or on the Company's brine, competitive risks and the availability of financing, as described in more detail in our recent securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303344919/en/
Contacts
E3 Lithium - Investor Relations Alexis de la RenaudiereInvestor Relationsinvestor@e3lithium.ca 587-324-2775
E3 Lithium - Media Inquiries Kati DolyniukExternal Relationscommunications@e3lithium.ca 587-324-2775

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

Yahoo

time3 hours ago

  • Yahoo

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the 'Company') announces that it will apply to the TSX Venture Exchange (the 'Exchange') to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein. Convertible Debenture Amendments The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the 'Convertible Debentures') issued pursuant to the Company's non-brokered private placement of Convertible Debenture units closed on May 29, 2023 (the 'Debenture Unit Private Placement'). The Convertible Debentures are governed by an indenture dated May 29, 2023 (the 'Indenture') between the Company and Odyssey Trust Company as the debenture trustee (the 'Debenture Trustee'). For further information relating to the Convertible Debentures and the Debenture Unit Private Placement, please refer the Company's press release dated May 29, 2023. The amendments, if approved by the requisite majority of holders of the Convertible Debentures (the 'Debentureholders'), will result in the following changes to the terms thereof (the 'Debenture Amendments'): the maturity of the Convertible Debentures will be extended from November 29, 2025 to June 6, 2028 (the 'Maturity Date'); the conversion price will be reduced from $2.00 per common share to $1.00 per common share; no redemption premium will be payable upon a redemption by the Company; and any interest that accrues on the Convertible Debentures following the Debenture Amendments will be due and payable on the Maturity Date. The Debenture Amendments remain subject to the approval of the Exchange and the holders of at least 66 2/3% of the outstanding principal of the Convertible Debentures. In accordance with the terms of the Indenture, the Company intends to obtain the requisite approval of the Debentureholders by way of a written consent. Upon and subject to receipt of the Exchange's approval, the Company intends to execute a supplemental indenture with the Debenture Trustee amending the terms of the Indenture to reflect the Debenture Amendments. Certain directors of the Company, as a group, beneficially own, control or direct, directly or indirectly, $100,000 principal amount of Convertible Debentures, representing approximately 6.9% of the outstanding principal amount of the Convertible Debentures. Participation by such persons constitutes a 'related party transaction' as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ('MI 61-101') and Exchange Policy 5.9 - Protection of Minority Security Holders in Special Transactions ('Policy 5.9'). The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves the related parties, exceeds 25% of the Company's market capitalization. Warrant Amendments The Company also intends to file an application with the Exchange to amend the terms of the currently outstanding 19,200,000 common share purchase warrants (the 'Warrants') previously issued pursuant to the Company's non-brokered private placement of units that closed in multiple tranches between June 26, 2024 and July 26, 2024 (the 'Unit Private Placement'). For further information relating to the Warrants and the Unit Private Placement, please refer the Company's press releases dated May 23, 2024, June 20, 2024, July 19, 2024, July 22, 2024, and July 26, 2024. Subject to the approval of the Exchange and the consent of the holders of the Warrants, the Company intends to amend the exercise price of the outstanding Warrants from $2.00 per common share (on a post-consolidation basis) to $0.75 per common share and reduce the term of the Warrants from three years from the original date of issuance (ranging from June 26, 2027 to July 19, 2027) to thirty days from the date of Exchange approval of the Warrant amendments (together, the 'Warrant Amendments'). To date, none of the Warrants have been exercised. A director of the Company, Jeffrey Bacha, beneficially owns, controls or directs, directly or indirectly, 100,000 Warrants, representing approximately 0.5% of the outstanding Warrants. Participation by Mr. Bacha constitutes a related party transaction under MI 61-101 and Policy 5.9. The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the Warrants held by Mr. Bacha does not exceed 25% of the Company's market capitalization. The Warrant Amendments remain subject to the approval of the Exchange. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Their work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, they can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Notice Regarding Forward-Looking Statements This press release may contain 'forward-looking statements' regarding the Company and its respective business within the meaning of applicable Canadian securities laws, including, without limitations, statements regarding: the Company's objectives, goals, or future plans regarding its cancer treatments or proposed business plan and expected results of the Company's DDR platform; the Debenture Amendments and the Warrant Amendments; and expectations regarding Exchange and Debentureholder approvals. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'is expected', 'expects', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at For Further Information Contact: Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@

Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President
Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President

Yahoo

time6 hours ago

  • Yahoo

Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President

Toronto, Ontario--(Newsfile Corp. - June 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") has received a Statement of Claim filed by Sherif Louis, the former President of the Company, in the amount of approximately $530,000 for notice and bonuses that he claims are owed to him. Telo intends to file a statement of defence and counterclaim and vigorously defend the claim. For further information, please contact:Guido BaechlerExecutive Chairman 647-477-9365info@ MaRS Centre, South Tower101 College Street, Suite 200Toronto, ON, M5G 1L7 Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's the amounts claimed and the Company's intent to defend the claim are subject to known and unknown risks, uncertainties and other factors that may cause the actual outcome to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. To view the source version of this press release, please visit Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

American Tungsten Corp. Announces Non-Brokered Private Placement of Shares
American Tungsten Corp. Announces Non-Brokered Private Placement of Shares

Hamilton Spectator

time7 hours ago

  • Hamilton Spectator

American Tungsten Corp. Announces Non-Brokered Private Placement of Shares

Vancouver, BC, June 30, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) ('American Tungsten' or the 'Company') is pleased to announce that it will proceed with a non-brokered private placement of up to 5,000,000 common shares of the Company (the 'Shares') at $0.50 per Share for gross proceeds of up to $2,500,000 (the 'Offering'). 'Securing this capital marks an important step forward for American Tungsten. It allows us to accelerate development of the IMA Tungsten Project and pursue additional strategic opportunities, positioning us to become a leading domestic source of this critical metal. As global demand for tungsten continues to rise, we are proud to advance a secure, North American supply chain that supports long-term growth,' stated Ali Haji, President and CEO of American Tungsten Corp. In connection with the Offering, the Company will pay finders' fees of up to 7.0% of the gross proceeds raised by the Company from the sale of Shares to subscribers directly introduced to the Company by eligible finders. In addition, the Company will issue to eligible finders non-transferable finders' warrants of up to 7.0% of the number of Shares sold in the Offering. Each finders' warrant will entitle the holder to acquire one Share at a price of $0.50 per Share for a period up to 24 months from the date of issuance, all in accordance with the policies of the Canadian Securities Exchange ('CSE'). The Company will use the net proceeds from the Offering to fund exploration work programs, option payments, mineral property acquisitions, marketing and for general working capital purposes. Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the CSE. The Offering is not subject to a minimum aggregate amount of subscriptions. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation and the CSE. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the 1933 Act or under any U.S. state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act, as amended, and applicable state securities laws. ABOUT AMERICAN TUNGSTEN CORP. American Tungsten Corp. is a Canadian exploration company focused on high-potential tungsten and magnetite portfolio in North America. The Company is advancing the Ima Mine Project in Idaho, a historic underground tungsten producer, where it holds an option to acquire full ownership (subject to a 2% royalty) and has expanded its land position with 113 additional federal claims covering nearly 2,000 acres. The Company's Star Project, spans over 4,600 hectares in British Columbia's Skeena Mining Division, where the company holds an option to earn 100% ownership. Social media links: LinkedIn: X: Facebook: corp/ Instagram: YouTube: ON BEHALF OF THE BOARD OF DIRECTORS: Ali Haji ‎Chief Executive Officer 1055 West Georgia Street, Suite 1500 Vancouver, BC V6E 0B6 Canada For further information, please contact: Ali Haji, Chief Executive Officer Email: ir@ Phone: +1 (647) 871-4571 CSE:TUNG OTCQB:DEMRF FSE:RK9 The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release. This news release includes 'forward-looking information' that is subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements may include but are not limited to, statements relating to the completion of the Offering on the terms described herein or at all, and the use of proceeds and available funds following the completion of the Offering and are subject to all of the risks and uncertainties normally incident to such events. Investors are cautioned that any such statements are not guarantees of future events and that actual events or developments may differ materially from those projected in the forward-looking statements. Such forward-looking statements represent management's best judgment based on information currently available. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store